The FDA has approved the first cholesterol-lowering pill that works by the same powerful mechanism as the leading injectable drugs, and clinical trial results show it works just as well. On July 16, 2026, Merck announced that the FDA approved Lipfendra (enlicitide) tablets 20 mg as a once-daily oral treatment for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The drug belongs to the PCSK9 inhibitor class, which had until now been available only as subcutaneous injections administered every two to four weeks.
In Phase 3 trials, Lipfendra cut LDL cholesterol by 56% in one trial and 59% in another at 24 weeks, both placebo-adjusted figures. That puts the pill's efficacy squarely in the same range as the injectable PCSK9 inhibitors already on the market.
Why This Matters
An estimated 73 million Americans have high LDL cholesterol, and cardiovascular disease remains the leading cause of death in the United States. For many patients who cannot get their LDL to target with statins alone, the PCSK9 inhibitor class has offered a highly effective second option. But adoption has been limited by a factor that has nothing to do with efficacy: the injections.
Some patients are not willing to self-inject. Others have practical barriers, including insurance authorization delays, limited access to specialty pharmacies that stock the biologics, and the logistical friction of a recurring injection schedule. For patients with familial hypercholesterolemia, a genetic condition that causes dangerously elevated LDL from birth and affects roughly 1 in 250 Americans, getting and staying on treatment is a lifelong imperative. A daily pill removes many of the barriers that have kept them off a drug class their risk profile demands.
What We Know So Far
Lipfendra is a novel macrocyclic peptide, a chemical structure that differs fundamentally from the injectable PCSK9 inhibitors, which are monoclonal antibodies. Macrocyclic peptide technology is what makes oral delivery possible: unlike large-molecule antibodies, these smaller, ring-shaped molecules can be absorbed through the gastrointestinal tract in sufficient amounts to exert a meaningful drug effect.
The approval was supported by two Phase 3 trials, CORALreef Lipids and CORALreef HeFH. In CORALreef Lipids, Lipfendra reduced LDL by a placebo-adjusted 56% at week 24. In CORALreef HeFH, the reduction was 59%. Both outcomes were statistically significant and clinically meaningful. Lipfendra is approved as an adjunct to diet and exercise, meaning it is intended to complement, not replace, lifestyle interventions and any existing statin therapy.
The drug was approved through the FDA's Commissioner's National Priority Voucher (CNPV) program, an initiative launched under former FDA Commissioner Marty Makary designed to accelerate reviews for medicines aligned with certain government priorities. Merck beat competitor AstraZeneca to market, as AstraZeneca's own oral PCSK9 candidate, AZD0780, remains in development.
Where the Impact Is Highest
The approval is most immediately significant for three patient populations. First, patients with heterozygous familial hypercholesterolemia, who carry a genetic mutation causing LDL levels that can be twice or more the normal range from birth. These patients often remain on multiple LDL-lowering therapies for their entire lives and represent the highest-urgency group for additional treatment options.
Second, patients who are already on statins but have not achieved their LDL target, particularly those who have tried and discontinued injectable PCSK9 therapy due to needle aversion or adherence difficulties. Third, patients in communities or healthcare systems where specialty pharmacy access to injectable biologics has been limited, where a standard oral prescription model may dramatically improve real-world access.
The Family Heart Foundation, which advocates for people living with familial hypercholesterolemia, called the approval "especially meaningful" for the FH community, noting that "people living with FH are born with high LDL-C and are exposed to its effects over a lifetime. Many need more than one treatment to lower their LDL-C."
What Doctors and Experts Say
"PCSK9 inhibitors are among our most potent LDL-lowering therapies, but until now they have primarily been available as injectable medications. Some patients may be hesitant to take an injectable medication, and others may face practical barriers that make injectable therapies more challenging," said Dr. Jeffrey Berger of NYU Langone Health, commenting to TCTMD at the time of approval.
Merck's chief scientific officer called Lipfendra the result of "harnessing the innovative science of PCSK9 inhibitors and novel macrocyclic peptide technology" to deliver injectable-class efficacy in a convenient once-daily pill. The company noted the drug was designed to significantly lower LDL in patients who need more than what statins alone can achieve.
One important limitation that cardiologists and patients should understand: the CORALreef Outcomes trial, a large cardiovascular outcomes study evaluating whether Lipfendra's LDL-lowering translates into reduced heart attacks and strokes, is ongoing and results are expected around 2029. The injectable PCSK9 inhibitors already have outcomes trial data demonstrating cardiovascular event reduction. Lipfendra does not yet have that evidence, and prescribers should account for this distinction when counseling patients.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Two Phase 3 randomized controlled trials (CORALreef Lipids, CORALreef HeFH)
- LDL reduction: 56% (CORALreef Lipids) and 59% (CORALreef HeFH), both placebo-adjusted at 24 weeks
- Population: Adults with hypercholesterolemia; second trial focused on heterozygous familial hypercholesterolemia
- Common adverse events (HeFH trial): Diarrhea (7% vs. 2% placebo) and dizziness (9% vs. 4% placebo)
- Discontinuation rate: Similar to placebo in both trials
- What it shows: Statistically significant, clinically meaningful LDL reduction in both trials, comparable to injectable PCSK9 inhibitors
- What it does not yet prove: Reduced cardiovascular events (heart attack, stroke, death); the outcomes trial (CORALreef Outcomes) is ongoing with results expected around 2029
- What readers should know: LDL reduction is an established surrogate marker for cardiovascular risk. The absence of outcomes data does not negate the drug's approval, but it is context patients and prescribers should know.
Who Is Most Likely to Benefit?
Adults most likely to benefit from Lipfendra include:
- People with persistently high LDL despite statin therapy, whether due to statin intolerance, inadequate response, or familial hypercholesterolemia
- People diagnosed with heterozygous familial hypercholesterolemia who need LDL reductions beyond what statins and ezetimibe can achieve
- People who have been recommended injectable PCSK9 therapy but have declined or discontinued due to needle aversion
- People for whom logistical access to injectable biologics has been a barrier (specialty pharmacy requirements, refrigeration needs, biweekly or monthly injection schedules)
- High-risk cardiovascular patients, including those who have had prior heart attacks or strokes, who need aggressive LDL lowering
Symptoms and Conditions This Drug Treats
Lipfendra does not treat symptoms; it addresses an underlying biochemical risk factor. The conditions it is approved for include:
- Hypercholesterolemia, meaning persistently elevated LDL cholesterol that increases cardiovascular risk
- Heterozygous familial hypercholesterolemia, an inherited condition caused by mutations in the LDL receptor gene that results in LDL levels that statins alone often cannot adequately reduce
Adults with hypercholesterolemia often have no symptoms until a cardiovascular event occurs. That is why screening and proactive treatment are the standard of care for people identified as high-risk through lipid panels and cardiovascular risk assessment.
What You Can Do Now
- If you have high LDL cholesterol that has not reached target with statins, speak with your cardiologist or primary care physician about whether Lipfendra is appropriate for your situation.
- If you have heterozygous familial hypercholesterolemia and are not at your LDL goal, ask your physician specifically about oral PCSK9 inhibitor options now that one is approved.
- If you have previously tried and stopped an injectable PCSK9 therapy due to needle concerns, contact your prescriber to discuss whether Lipfendra could be substituted.
- Do not stop any existing cholesterol medication without speaking with a health care provider first.
- Check with your insurance plan about coverage. Merck has not yet published list pricing; insurance and prior authorization determinations for new drugs often take several weeks to months to be finalized after approval.
Cost and Access: What Patients Should Know
Merck has not publicly released the list price for Lipfendra as of July 20, 2026. Injectable PCSK9 inhibitors have carried list prices in the range of $5,000 to $7,000 annually, though insurance and manufacturer discount programs have frequently reduced out-of-pocket costs for eligible patients. Whether Lipfendra will be priced similarly or differently, and how payers will position it relative to existing options, will be central to its real-world uptake.
Patients with commercial insurance, Medicare Part D, or Medicaid should speak with their pharmacist or prescriber's office about coverage and prior authorization requirements, which are common for this drug class. Merck typically offers a patient assistance program for commercially uninsured patients meeting financial eligibility criteria; patients should contact Merck directly for current program details.
What Happens Next
The CORALreef Outcomes cardiovascular outcomes trial is ongoing, with results expected around 2029. That data will determine whether Lipfendra's LDL-lowering translates into the same kind of heart attack and stroke reduction already proven for injectable PCSK9 inhibitors. MedicalDaily will report on pricing announcements, insurance coverage developments, and any prescribing guideline updates as the cardiology community incorporates this approval into clinical practice.
The Bottom Line
Lipfendra represents the first genuinely new option in the PCSK9 inhibitor class since the injectables launched nearly a decade ago, and it removes the single largest real-world barrier to patient access: the need for injections. The LDL-lowering data are strong and comparable to injectables. The cardiovascular outcomes data are pending. For the millions of Americans with high LDL who are not at goal, and particularly for the estimated 1.3 million with familial hypercholesterolemia, this approval opens a conversation that many patients and their doctors have been waiting to have.
